|
|
|
|
|
|
|
Request your FREE Special Report today and you'll |
Shares of Biodel Inc. (Nasdaq: BIOD) are plummeting in pre-market trading despite the pharmaceutical’s positive report that two phase III trials for treatment of patients with Type 1 and Type 2 diabetes met their endpoints.
Shares plunged 53%, or $9.04, to $8 in pre-market trading. For detailed price information and news stories on Biodel, click BIOD.
Join Daily Profit today and get our unique perspective and investment ideas in your inbox every day.
Please tell us where we can send your free subscription. Plus, as a free gift, I'll rush you a copy of my Top 10 Forever Stocks - a special bonus report.
Wyatt Investment Research
c/o Business Financial Publishing
65 Railroad Street
PO Box 790
Richmond, VT 05477
